PMC8408045_01
The changes of Physical examination. (A) Physical examination on admission. (B) "EC" chemotherapy. (C) "PCb" chemotherapy. (D) the administration of anlotinib.
OTT-14-4599-g0001.jpg
PMC8408045_01_OTT-14-4599-g0001.jpg
f0001
On October 20, 2018, the patient was given the "EC" chemotherapy regimen (epirubicin 130 mg d1; cyclophosphamide 0.8 mg d1), and its efficacy was evaluated as progressive disease (PD) after 2 cycles (Figure 1B). During chemotherapy, the patient's mass increased significantly (Figure 1C), bleeding was obvious, and the efficacy was still evaluated as PD. After the administration of anlotinib, the tumor spontaneously detached again and did not increase in size (Figure 1D), and the sternum metastasis was stable.
The pathological examination of postoperative. (A) Some lamellar tumor cells, different sized cells, atypia, coarse chromatin, obvious nuclear division, and osteoclast-like cells. (B) Some tumor cells were tubular, while some were fusiform and atypical, with different sizes and in different stages of nuclear division. (C) Some cells are necrosis in the center of the tumor. (D) VIM (+) (4X10). (E) CD56 (+) (4X10). (F) ki-67 40% (4X10). (G) ER (-) (10X10). (H) PR (-) (10X10).
OTT-14-4599-g0002.jpg
PMC8408045_01_OTT-14-4599-g0002.jpg
f0002
The postoperative pathological examination (Figure 2A-H) showed some lamellar tumor cells, different sized cells, atypia, coarse chromatin, obvious nuclear division, and osteoclast-like cells.